tedopi
ose immunotherapeutics
['tedopi', 'oseimmuno']
we presented four posters at the american society of clinical oncology (asco), 2022 annual meeting, featuring neoepitope specific immunotherapy tedopi in various cancer indications. read more on the poster presentations here: #asco22 
focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immune-oncology and auto-immune diseases.